Search

News Sport Therapy as Part of Hemophilia Management

A study by authors from the University of Wuppertal in Germany specifically examined the impact of a half-year programmed sport therapy on the subjective physical performance and quality of life of individuals with hemophilia.

Source: Hemophilia with Movement 27. 10. 2020

News Can identifying alpha-1 antitrypsin deficiency before liver transplantation extend survival?

Alpha-1 antitrypsin deficiency (AATD) can manifest (among other things) as liver cirrhosis. The study presented below examined the survival of patients diagnosed with AATD before and after liver transplantation.

Source: Deficiency of Alpha-1-Antitrypsin 1. 7. 2021

News How do Hemodialysis Patients Perceive the Coronavirus Pandemic? Survey Results

Hemodialysis patients are at higher risk of SARS-CoV-2 infection due to repeated visits to medical facilities. Additionally, these are often older and comorbid patients living in nursing homes. This study, presented below, examines how these patients perceived anti-epidemic measures during the first wave of the pandemic and how this extraordinary situation impacted their mental state.

Source: Chronic Kidney Disease 26. 1. 2021

News Impact of Tofacitinib on the Quality of Life of Patients with Ulcerative Colitis

Tofacitinib is an oral Janus kinase (JAK) inhibitor used in the treatment of certain rheumatic diseases and ulcerative colitis (UC). The work presented at this year's 18th congress of the European Crohn's and Colitis Organization (ECCO) in Copenhagen, Denmark, focused on its impact on the quality of life in terms of physical and mental functions in patients with UC.

Source: Intestinal Inflammations 7. 12. 2023

News Dosing and Consumption of rFVIII Products with Extended Half-life in Patients with Hemophilia A in Real-World Practice

Based on real-world data from the USA, a recently published study compared two recombinant human factor VIII (rFVIII) products with extended half-life (EHL) –⁠ efmoroctocog alfa and rurioctocog alfa pegol, in terms of dosing frequency, weekly consumption, and dose variability.

Source: Hemophilia 11. 4. 2023

News Administration of Erdosteine after Severe COVID-19 in the Early Period after Discharging Patients from the Healthcare Facility

Erdosteine is a mucomodulatory drug used in the treatment of various acute and chronic respiratory diseases. According to available evidence, its mechanism of action is complex, encompassing not only a mucolytic effect but also antioxidant and antibacterial properties. Two clinical studies evaluated changes in respiratory distress parameters and quality of life in patients using this medication in the early period after discharge from a healthcare facility where they were hospitalized due to severe COVID-19.

Source: Cough Therapy 28. 2. 2022

News Administration of Erdosteine After Severe Course of COVID-19 in the Early Period After Patient Discharge From Medical Facility

Erdosteine is a mucomodulatory drug used in the therapy of various acute and chronic respiratory diseases. Its mechanism of action is considered complex based on available evidence, encompassing antioxidant and antibacterial effects along with its mucolytic effect. Two clinical studies assessed changes in respiratory distress parameters and quality of life in patients taking this medication in the early period after discharge from medical facilities where they were hospitalized for severe COVID-19 (respiratory failure, pneumonia).

Source: Cough Therapy 8. 4. 2022

News Maintenance of Remission with Tofacitinib in Patients with UC –⁠ Results of the OCTAVE Open Study

Tofacitinib is indicated for the treatment of ulcerative colitis (UC) in cases where conventional treatment or monoclonal antibodies do not yield sufficient results. Key benefits of this medication include oral administration and predictable kinetics. The long-term efficacy of tofacitinib was studied in the OCTAVE Open study.

Source: Intestinal Inflammations 28. 5. 2022

News How Does Emicizumab Work in Obese Adults with Hemophilia A?

What is the annual bleeding rate and minimum concentration of emicizumab in obese adults with hemophilia A compared to non-obese individuals? Answers were sought by the authors of a pooled post hoc analysis of the HAVEN 1, 3, and 4 studies, the results of which were presented in the poster section of the 2021 ISTH virtual congress. Based on modeling, body weight appears to be an important predictor of emicizumab pharmacokinetics.

Source: Quality Life Even with Hemophilia 1. 12. 2021

News When to Stop Dabigatran Anticoagulation Treatment Before Catheter Ablation in Patients with Atrial Fibrillation?

Catheter ablation is now a standard method of treating atrial fibrillation. Its most common complications are bleeding and thromboembolism. The aim of the analysis of 2 clinical studies presented below, whose conclusions were recently published, was to determine the optimal timing of stopping dabigatran anticoagulation treatment before this procedure.

Source: Anticoagulant Treatment 22. 7. 2021

News Antiviral and Anti-inflammatory Effects of Alpha-1-Antitrypsin in the Treatment of COVID-19

Human alpha-1-antitrypsin (AAT) is a circulating blood glycoprotein that has been used for decades in the treatment of patients with AAT deficiency, lung damage, and emphysema, helping to prevent acute lung injury. Recently, it has been found that AAT also mitigates the course of COVID-19 disease by hindering the entry of the SARS-CoV-2 coronavirus into host cells. This dual antiviral and anti-inflammatory action makes AAT an excellent candidate for COVID-19 treatment.

Source: Deficiency of Alpha-1-Antitrypsin 14. 5. 2021

News Effect of Trifluridine/Tipiracil Combination Depending on Patient Prognosis

The results of the RECOURSE clinical study were published in 2015 and became an important basis for the approval of the trifluridine/tipiracil combination in the treatment of metastatic colorectal cancer (mCRC). The data obtained in this study were also subjected to several post-hoc analyses. One of these recently brought information on how patient prognosis affects the clinical outcomes of this treatment.

Source: Treatment of Gastrointestinal Carcinomas 19. 6. 2020

News Do real-world clinical practice data confirm the results of cenobamate treatment in the clinical program?

A recent study by Spanish authors presents the largest dataset of patients with published cenobamate treatment results under prolonged observation in real-world clinical practice at the time of article publication. Data are derived from an expanded access program for a population with highly drug-resistant focal seizures.

Source: Epilepsy 13. 9. 2023

News Thromboprophylaxis in Generalized Pancreatic Cancer

Pancreatic adenocarcinoma is one of the tumors with the highest risk of developing thromboembolic disease (TED). Although anticoagulant treatment reduces the risk of TED, its positive effect on the overall survival of patients has not yet been proven.

Source: Thromboprophylaxis 28. 5. 2021

News Venetostart –⁠ The First Comprehensive Mobile Application with Practical Information for Venetoclax Treatment

Abbvie has developed the comprehensive mobile application Venetostart with practical information needed in clinical practice for administering venetoclax (Venclyxto), which is indicated for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).

Source: Chronic Lymphocytic Leukemia 27. 2. 2023